Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.5900
+0.01803.15%
Pre-market: 0.5830-0.0070-1.19%09:11 EDT
Volume:4.24M
Turnover:2.51M
Market Cap:143.37M
PE:-0.79
High:0.6066
Open:0.6023
Low:0.5800
Close:0.5720
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:198.00M
Volume Ratio:0.72
T/O Rate:2.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-13.80
PE(LYR):-0.33

Loading ...

Outlook Therapeutics says FDA accepts resubmitted Lytentava BLA for wet AMD review

Reuters
·
Jun 16

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for Ons-5010/Lytenava™ (Bevacizumab-Vikg) as a Treatment for Wet Amd

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics - Pdufa Target Action Date Set for July 29, 2026

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics - Initiates Pre-Launch Activities for Ons-5010/Lytenava

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics director Yezan Munther Haddadin acquires 29,000 common shares for $24,145.40

Reuters
·
Jun 04

Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase

Reuters
·
Jun 02

Outlook Therapeutics Resubmits Lytenava Biologics License Application to FDA

MT Newswires Live
·
Jun 01

Outlook Therapeutics resubmits FDA BLA for Lytneava in wet AMD

Reuters
·
Jun 01

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for Ons-5010/Lytenava™ (Bevacizumab-Vikg)

THOMSON REUTERS
·
Jun 01

Outlook Therapeutics - FDA Says No Additional Trials Required for Lytenava in Namd

THOMSON REUTERS
·
Jun 01

Outlook Therapeutics Prices Offering of Common Shares

MT Newswires Live
·
May 29

Outlook to sell 8.54M shares at 58.55c in registered direct offering

TIPRANKS
·
May 29

Outlook Therapeutics prices USD 5 million registered direct offering at USD 0.59 per share

Reuters
·
May 29

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
May 29

Outlook Therapeutics director Yezan Munther Haddadin acquires 34,000 common shares worth $14,960

Reuters
·
May 28

Outlook Therapeutics director Kurt J. Hilzinger acquires 400,000 common shares for $176,520

Reuters
·
May 28

BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment

Reuters
·
May 26

Outlook Therapeutics wins appeal following FDR process for ONS-5010/Lytenava

TIPRANKS
·
May 26

Outlook Therapeutics Inc - to Resubmit Ons-5,010/Lytenava Bla in June 2026

THOMSON REUTERS
·
May 26

Outlook Therapeutics Inc - FDA Finds Substantial Evidence of Effectiveness for Lytenava in Namd

THOMSON REUTERS
·
May 26